Home / Business and Economy / Lilly Bets Big on China: $3B for Weight-Loss Drugs
Lilly Bets Big on China: $3B for Weight-Loss Drugs
11 Mar
Summary
- Eli Lilly commits $3 billion to China over ten years.
- Investment prioritizes manufacturing of orforglipron, a weight-loss pill.
- Partnerships with local firms like Pharmaron enhance production capabilities.
Eli Lilly & Co. is set to invest $3 billion in China over the next ten years, aiming to significantly expand its local manufacturing operations. This substantial investment is strategically focused on the rapidly growing obesity market, positioning Lilly to solidify its leadership.
A key aspect of this expansion will involve establishing production facilities for orforglipron, the company's weight-loss pill. This drug is currently under regulatory review within China. Lilly's strategy also includes forging collaborations with local Chinese pharmaceutical firms.
One such partnership is with Pharmaron Beijing Pharmaceutical Co., involving a $200 million deal. This collaboration aims to build technical capabilities for producing orforglipron and other upcoming treatments, enhancing Lilly's overall production network in the region.
